US-based medical technology manufacturer Peytant Solutions Inc announced on Tuesday that it has received marketing authorisation from the US Food and Drug Administration (FDA) for its AMStent Tracheobronchial Covered Stent System, a novel, proprietary therapy platform.

The product is indicated for use in the treatment of tracheobronchial strictures produced by malignant neoplasms in adult patients. It is the first product offering within the company's amnion-based covered stent platform and is designed to treat pulmonary obstructions caused by cancer.

John Schorgl, Peytant cofounder and CEO, said: "'We are optimistic that the AMStent System will prove to be a much-needed option for patients suffering from tracheobronchial obstruction due to malignant tumours. With the availability of the AMStent System, we hope to improve the palliative care and thereby the quality of life for these patients."